Aduro Announces First Patient Dosed in Phase 1 Study of ADU-S100 (MIW815) in Combination with YERVOY (ipilimumab) for the Treatment of Relapsed and Refractory Melanoma
Aduro Biotech announced that the first patient has been dosed in a Phase 1 trial of ADU-S100 (MIW815), a novel...
Read more
André van de Sande ambassador and advisor to Pivot Park
André van de Sande has recently been appointed as ambassador and advisor to the Pivot Park in Oss. Together with...
Read more
Foundation laid for new Q fever vaccine
Three years of research at, among others, Innatoss Laboratories in Oss laid the foundation for a new Q fever vaccine....
Read more
Scientist Silvie Meeuwissen: “My interest is mainly in the practical applications of chemistry”
Silvie Meeuwissen (1985) has been working as a Principal Scientist at ChemConnection B.V. since 2014. The company that was founded in 2012 by two former Organon employees is one of the few companies in Europe that focuses on commercialization of medical applications for nanotechnology.
Read more
New at Pivot Park – Agidens
Agidens is a Belgian company and helps customers in improving processes by means of specialty advice, engineering, automation solutions and...
Read more
Synaffix ADC Technology enters the clinic
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors Pyrrolobenzodiazepine-based antibody drug...
Read more
A cup of coffee with… Cindy Oppers
“PPSC crossed my path and I didn’t want to let this opportunity pass me by.” Recently Cindy Oppers started as...
Read more
Synaffix Announces License Agreement with Mersana Therapeutics
Synaffix announced it has entered into a license agreement with Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering...
Read more